| # | Country | Total Patents | |
|---|---|---|---|
| #1 | WIPO (World Intellectual Property Organization) | 3 | |
| #2 | Taiwan | 2 | |
| #3 | Australia | 1 | |
| #4 | Brazil | 1 | |
| #5 | Canada | 1 | |
| #6 | China | 1 | |
| #7 | EPO (European Patent Office) | 1 | |
| #8 | Republic of Korea | 1 |
| # | Industry | |
|---|---|---|
| #1 | Pharmaceuticals | |
| #2 | Biotechnology |
| # | Technology | |
|---|---|---|
| #1 | Medical preparations | |
| #2 | Peptides | |
| #3 | Therapeutic chemical compounds |
| # | Name | Total Patents |
|---|---|---|
| #1 | Wu Chengbin | 10 |
| #2 | Gong Shiyong | 8 |
| #3 | Wu Xuan | 7 |
| #4 | Gong Shi-Yong | 2 |
| #5 | Chengbin Wu | 1 |
| #6 | Shiyong Gong | 1 |
| #7 | Ren Fang | 1 |
| #8 | Xuan Wu | 1 |
| Publication | Filing date | Title |
|---|---|---|
| WO2021056610A1 | High affinity antibodies to cd39 and uses thereof | |
| TW202035448A | Efficiently expressed egfr and pd-l1 bispecific binding proteins | |
| BR112020022371A2 | high affinity antibodies to pd-1 and lag-3 and bispecific binding proteins produced from them |